ACRS Q3 2024 Earnings — Aclaris Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

ACRSAclaris Therapeutics, Inc.

$435M

Q3 2024 Earnings

Healthcare Medical - Diagnostics & Research

Income Statement

Revenue

$4M-53.2% YoY

Gross Profit

$2M44.6% margin

Operating Income

-$10M-240.9% margin

Net Income

-$8M-174.6% margin

EPS (Diluted)

$-0.11

QoQ Revenue Growth

+57.1%

Cash Flow

Operating Cash Flow

$22M

Free Cash Flow

$22M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$182M

Total Liabilities

$52M

Stockholders' Equity

$130M

Cash & Equivalents

$48M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$4M	$9M	-53.2%
Gross Profit	$2M	$1M	+77.8%
Operating Income	-$10M	-$32M	+66.8%
Net Income	-$8M	-$29M	+74.1%

Revenue Segments

License and Service

$4M85%

Contract research

$645,00015%